New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTNEPT, ENZY, ACSTNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Check below for free stories on NEPT;ACST;ENZY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
14:05 EDTENZY, NEPTNeptune says '348 patent still valid, to appeal USPTO decision
Neptune Technologies & Bioressources (NEPT) announced that the United States Patent and Trademark Office, or USPTO, recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's '348 patent. Despite the USPTO's decision, the '348 patent is still valid as Neptune has the right to appeal, which it intends to do, the company said. "Enzymotec (ENZY), in yet another clear attempt to shift focus from the on-going International Trade Commission investigation of its infringement of other Neptune patents, issued a press release addressing the '348 Patent decision. However, Enzymotec failed to highlight that the decision has no impact on the ITC investigation into infringement of Neptune's other composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Furthermore, the decision has no impact on Neptune's license agreements with Rimfrost and Aker BioMarine," said Neptune.
08:09 EDTENZY, NEPTEnzymotec says USPTO issues final decision, rejects all claims in Neptune patent
Subscribe for More Information
April 10, 2014
16:09 EDTNEPTGeorge Haywood reports 9.9% stake in Neptune Technologies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use